Business Context and Reporting Period
This Form 8-K, dated March 31, 2009, serves as a Regulation FD disclosure for MediciNova, Inc. It references a Japanese financial report ("Kessan Tanshin") filed on April 1, 2009, with the Osaka Securities Exchange. The filing provides supplemental financial forecasts for the fiscal year ending December 31, 2009, and the interim period ending June 30, 2009, alongside supplementary financial statements denominated in Japanese yen.
Key Financial Metrics and Guidance
The filing contains forward-looking financial estimates for 2009 rather than historical results for the current period. Key forecasted metrics include:
- Revenues: $0 (No revenue expected for the interim or full year).
- Operating Loss (Interim 6 months): $(10,828,000).
- Net Loss (Interim 6 months): $(10,630,000).
- Operating Loss (Full Year): $(19,640,000).
- Net Loss (Full Year): $(19,318,000).
- Expected Loss Per Share (Full Year): $1.61 (Basic and diluted, based on 12,023,320 weighted average shares).
- Cash Burn: Anticipated to be less than $16.0 million for the fiscal year ending December 31, 2009.
Supplementary financial statements in Japanese yen were translated using an exchange rate of 91.03 yen per U.S. dollar as of December 30, 2008.
Material Changes and Prior Period Comparison
The filing states that the Japanese "Tanshin" report is substantially the same as the Company's Annual Report on Form 10-K for the year ended December 31, 2008, with the addition of the 2009 forecasts and yen-denominated statements. The text does not provide specific historical financial figures for the prior period to calculate year-over-year material changes.
Outlook, Risks, and Contingencies
Management emphasizes that the provided estimates are based on assumptions regarding current conditions and trends. The filing includes extensive disclaimers regarding forward-looking statements, noting that actual results may differ materially due to various risks, including:
- Uncertainty in clinical trial results and product development timelines.
- Risks of regulatory approval delays or failures.
- Reliance on third parties for clinical trials and manufacturing.
- Potential cost increases and delays in clinical trial execution.
- Ability to raise sufficient capital and availability of funds.
- Market factors, including credit market uncertainties and currency exchange rate fluctuations.
Independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the Company's actual cash position and runway against the projected cash burn of less than $16.0 million.
- Review the Form 10-K for the year ended December 31, 2008, to compare historical performance against the 2009 loss forecasts.
- Monitor progress of clinical trials and regulatory filings, as these are primary drivers of the forecasted losses and future viability.
- Assess the Company's ability to secure additional capital given the projected net loss of approximately $19.3 million.
- Confirm the weighted average share count of 12,023,320 used for the loss per share calculation.